Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07164092

Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center

This randomized controlled trial aims to evaluate the efficacy and safety of low-dose topical atropine sulphate (0.05%), a non-selective muscarinic antagonist, in slowing the progression of myopia and ocular axial elongation in children. The study will be conducted at Mansoura Ophthalmic Center, Mansoura University, Egypt, from October 2025 to october 2027.

Eligible participants are myopic children attending the outpatient clinic during the study period. Participants will be stratified into three groups according to baseline myopia severity (low, moderate, and high). Each child will be randomized to receive one drop of atropine 0.05% in one eye and one drop of placebo in the fellow eye nightly for 24 months. The allocation of treatment to right or left eye will be randomized to avoid laterality bias.

Study Outcomes

* Primary Outcome

o Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation. * Secondary Outcomes

* Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%. * Best-corrected distance visual acuity (BCVA). * Sample Size

The primary endpoint of this trial is the change in ocular axial length (AL) over 24 months, analyzed as a paired comparison between the atropine-treated and placebo-treated eyes within each child.

Sample size estimation was based on previously published data reporting mean axial elongation of 0.115 ± 0.11 mm in atropine-treated eyes compared with 0.303 ± 0.12 mm in placebo-treated eyes, yielding a mean difference of 0.188 mm. Assuming an inter-eye correlation of 0.6, the standard deviation of the paired difference is estimated at approximately 0.10 mm, giving an effect size of d = 1.88. Using a two-tailed paired t-test with α = 0.05 and 90% power, the minimum required sample size is 12 children.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

3 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Myopia of at least -1.0 D in both eyes, astigmatism of less than 2.0 D, anisometropia of objective spherical equivalent ≤ 1.50 D.
  • Documented myopic progression of at least 0.5 D in the past one year.

Exclusion criteria

  • Children with ocular or systemic diseases that potentially influence myopia or refractive power.
  • Ocular diseases, e.g., cataracts, glaucoma
  • Posterior segment hereditary and acquired pathological disorders.
  • History of any previous ocular surgery.
  • History of any ocular injuries.
  • Previous use of interventions (such as atropine, pirenzepine, orthokeratology lens, or other optical methods) for myopia control
  • Allergy to atropine, cyclopentolate or benzalkonium chloride

Treatment and study plan

Atropine 0.05% Eye drops

Drug

The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.

Placebo Ophthalmic Solution

Drug

The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.

Primary outcomes

  1. Change in ocular axial length (AL)

    Time frame: 2 years

    Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation

Secondary outcomes

  1. Change in spherical equivalent refraction (SER

    Time frame: 24 months

    Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%.

  2. Best-corrected distance visual acuity (BCVA).

    Time frame: 24 months

Study contacts

Contact information is provided by the study sponsor or research team.

Ghada H. Allam, Dr

CONTACT

[email protected]

+201062838323

Sponsors and collaborators

Lead sponsor

Mansoura University

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 9, 2025
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.